Reagent Development for Toll-like and Other Innate Immune Receptors (U24)

The summary for the Reagent Development for Toll-like and Other Innate Immune Receptors (U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Reagent Development for Toll-like and Other Innate Immune Receptors (U24): Purpose. The National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (NIH), invites new applications from institutions with multidisciplinary research teams to participate in the development of new reagents for Toll-like and other innate immune pattern recognition receptors (PRRs). The goal of this Funding Opportunity Announcement (FOA) is to support the development and wide distribution of reagents to the scientific community for use as research tools to study the expression and physiological functions of PRRs in humans and animal model systems. Examples of reagents to be created and characterized include antibodies, soluble receptors, fusion proteins, RNA-based inhibitors, and small molecules. Awardees will form an interactive Steering Committee to share information, expertise, and resources leading to the rapid development of novel research tools. In addition, an External Advisory Group will be formed by the NIAID after award to provide critical advice on reagent prioritization and changes in experimental methods or directions. The overall goal of this program is to facilitate the development of new vaccines, therapeutics, and diagnostics for the prevention and treatment of existing, emerging, and re-emerging infectious diseases.
Federal Grant Title: Reagent Development for Toll-like and Other Innate Immune Receptors (U24)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-AI-08-021
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.85593.856
CFDA Descriptions: Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research
Current Application Deadline: No deadline provided
Original Application Deadline: Jul 22, 2008
Posted Date: Mar 21, 2008
Creation Date: Mar 21, 2008
Archive Date: Aug 22, 2008
Total Program Funding: $2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Public housing authorities/Indian housing authorities County governments Independent school districts Private institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Special district governments Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Public and State controlled institutions of higher education
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster